The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for ...

The FDA approved epcoritamab plus R 2 on November 18 for the treatment of patients with relapsed or refractory FL. It also ...

Miami sophomore forward Marcus Allen has been diagnosed with non-Hodgkin lymphoma and will miss the rest of the season.

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...

Roche’s FDA approval of Lunsumio VELO as a one-minute subcutaneous bispecific therapy for relapsed or refractory follicular ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

The future treatment landscape for follicular lymphoma is being rapidly shaped by several promising agents and novel ...

Follicular lymphoma is often underrecognized not only for its clinical complexity but also for the significant financial ...

Miami Hurricanes guard Marcus Allen will miss the rest of the 2025-2026 season as he undergoes treatment for non-Hodgkin ...

Miami Hurricanes sophomore forward Marcus Allen will miss the remainder of the season after being diagnosed with non-Hodgkin ...

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide for adult ...